| Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation PA Jänne, GJ Riely, SM Gadgeel, RS Heist, SHI Ou, JM Pacheco, ... New England Journal of Medicine 387 (2), 120-131, 2022 | 405 | 2022 |
| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ... Clinical Cancer Research 24 (24), 6195-6203, 2018 | 342 | 2018 |
| Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 158 | 2019 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 138 | 2021 |
| Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ... Journal of Thoracic Oncology 15 (9), 1449-1459, 2020 | 130 | 2020 |
| A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components MB Nilsson, H Sun, J Robichaux, M Pfeifer, U McDermott, J Travers, ... Science translational medicine 12 (559), eaaz4589, 2020 | 121 | 2020 |
| OA02. 06 a phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC) J Heymach, M Negrao, J Robichaux, B Carter, A Patel, M Altan, ... Journal of Thoracic Oncology 13 (10), S323-S324, 2018 | 117 | 2018 |
| STING pathway expression identifies NSCLC with an immune-responsive phenotype CM Della Corte, T Sen, CM Gay, K Ramkumar, L Diao, RJ Cardnell, ... Journal of Thoracic Oncology 15 (5), 777-791, 2020 | 108 | 2020 |
| PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non–small … MV Negrao, VK Lam, A Reuben, ML Rubin, LL Landry, EB Roarty, ... Journal of Thoracic Oncology 14 (6), 1021-1031, 2019 | 88 | 2019 |
| Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target X Le, MV Negrao, A Reuben, L Federico, L Diao, D McGrail, M Nilsson, ... Journal of thoracic oncology 16 (4), 583-600, 2021 | 72 | 2021 |
| Poziotinib for patients with HER2 exon 20 mutant non–small-cell lung cancer: Results from a phase II trial YY Elamin, JP Robichaux, BW Carter, M Altan, DL Gibbons, FV Fossella, ... Journal of Clinical Oncology 40 (7), 702, 2022 | 71 | 2022 |
| Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC FH Knebel, F Bettoni, AK Shimada, M Cruz, JV Alessi, MV Negrão, ... Lung Cancer 108, 238-241, 2017 | 69 | 2017 |
| Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial T Cascone, CH Leung, A Weissferdt, A Pataer, BW Carter, MCB Godoy, ... Nature medicine 29 (3), 593-604, 2023 | 65 | 2023 |
| Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer L Federico, DJ McGrail, SE Bentebibel, C Haymaker, A Ravelli, MA Forget, ... Annals of Oncology 33 (1), 42-56, 2022 | 63 | 2022 |
| Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC PO Gaudreau, MV Negrao, KG Mitchell, A Reuben, EM Corsini, J Li, ... Journal of Thoracic Oncology 16 (1), 127-139, 2021 | 62 | 2021 |
| STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition P Sitthideatphaiboon, A Galan-Cobo, MV Negrao, X Qu, A Poteete, ... Clinical Cancer Research 27 (6), 1720-1733, 2021 | 56 | 2021 |
| Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations MV Negrao, VM Raymond, RB Lanman, JP Robichaux, J He, MB Nilsson, ... Journal of Thoracic Oncology 15 (10), 1611-1623, 2020 | 53 | 2020 |
| Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity YY Elamin, JP Robichaux, BW Carter, M Altan, H Tran, DL Gibbons, ... Cancer Cell 40 (7), 754-767. e6, 2022 | 52 | 2022 |
| Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non–small-cell lung cancer (NSCLC) YY Elamin, DR Gomez, MB Antonoff, JP Robichaux, H Tran, MK Shorter, ... Clinical Lung Cancer 20 (1), 43-47, 2019 | 51 | 2019 |
| Sorafenib for the treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysis LA De Castroneves, MV Negrão, RMC De Freitas, C Papadia, JV Lima Jr, ... Thyroid 26 (3), 414-419, 2016 | 50 | 2016 |
